MedTrace Logo

Preconceptional Thromboprophylaxis in Recurrent PREGNANCY LOSSES Caused by Antiphospholipid Syndrome

NCT01661439 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 316

Last updated 2014-06-23

No results posted yet for this study

Summary

Preconceptional use of low molecular weight heparin (enoxaparin) and aspirin in patient with recurrent miscarriages with positive anti phospholipid antibodies increase the implantation rate and the duration of pregnancy with low complications to the mother and the baby.

Conditions

  • Recurrent Pregnancy Losses
  • Positive Anti Phospholipid Syndrome

Interventions

DRUG

low molecular weight heparin (enoxeparine)

1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.

Sponsors & Collaborators

  • Woman's Health University Hospital, Egypt

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01661439 on ClinicalTrials.gov